JP2017509692A - 喘息肺におけるｉｌ−１３活性化の末梢バイオマーカーとしてのジペプチジルペプチターゼ４（ｄｐｐ４／ｃｄ２６） - Google Patents

喘息肺におけるｉｌ−１３活性化の末梢バイオマーカーとしてのジペプチジルペプチターゼ４（ｄｐｐ４／ｃｄ２６） Download PDF

Info

Publication number
JP2017509692A
JP2017509692A JP2016566866A JP2016566866A JP2017509692A JP 2017509692 A JP2017509692 A JP 2017509692A JP 2016566866 A JP2016566866 A JP 2016566866A JP 2016566866 A JP2016566866 A JP 2016566866A JP 2017509692 A JP2017509692 A JP 2017509692A
Authority
JP
Japan
Prior art keywords
dpp4
patient
level
seq
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016566866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509692A5 (enExample
Inventor
ストレイチャー，カティ
ヤオ，イーホン
ラネード，コウストゥブー
リャン，メイナ
ヴァインシュテイン，インナ
パイパー，エドワード
メイ，リチャード
ノーデンマーク，ラーズ
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2017509692A publication Critical patent/JP2017509692A/ja
Publication of JP2017509692A5 publication Critical patent/JP2017509692A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
JP2016566866A 2014-01-27 2015-01-26 喘息肺におけるｉｌ−１３活性化の末梢バイオマーカーとしてのジペプチジルペプチターゼ４（ｄｐｐ４／ｃｄ２６） Pending JP2017509692A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461931878P 2014-01-27 2014-01-27
US61/931,878 2014-01-27
US201461990932P 2014-05-09 2014-05-09
US61/990,932 2014-05-09
PCT/US2015/012885 WO2015112970A1 (en) 2014-01-27 2015-01-26 Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung

Publications (2)

Publication Number Publication Date
JP2017509692A true JP2017509692A (ja) 2017-04-06
JP2017509692A5 JP2017509692A5 (enExample) 2018-03-08

Family

ID=53682019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566866A Pending JP2017509692A (ja) 2014-01-27 2015-01-26 喘息肺におけるｉｌ−１３活性化の末梢バイオマーカーとしてのジペプチジルペプチターゼ４（ｄｐｐ４／ｃｄ２６）

Country Status (12)

Country Link
US (1) US20160363591A1 (enExample)
EP (2) EP3685857A1 (enExample)
JP (1) JP2017509692A (enExample)
KR (1) KR20160113700A (enExample)
CN (1) CN105934254A (enExample)
AU (1) AU2015209124A1 (enExample)
BR (1) BR112016017192A2 (enExample)
CA (1) CA2937387A1 (enExample)
MX (1) MX2016009491A (enExample)
RU (1) RU2016134838A (enExample)
SG (1) SG11201606102UA (enExample)
WO (1) WO2015112970A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015214103A1 (en) * 2014-02-07 2016-07-21 Abbott Laboratories Novel assay to detect human periostin
KR20170098941A (ko) 2015-01-09 2017-08-30 메디뮨 엘엘씨 인간 dpp-4를 검출하기 위한 검정법
JP2018538249A (ja) * 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
JP6995844B2 (ja) * 2016-09-23 2022-02-04 ジェネンテック， インコーポレイテッド アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
WO2018156734A1 (en) * 2017-02-24 2018-08-30 Trustees Of Boston University Isolation of human lung progenitors derived from pluripotent stem cells
CN109055522A (zh) * 2018-07-03 2018-12-21 吉林大学 C4orf38在制备用于检测或治疗神经性疼痛的产品中的应用
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN113155996A (zh) * 2021-03-23 2021-07-23 广州医科大学附属第一医院（广州呼吸中心） 15(s)-羟基二十碳四烯酸在评估变应原特异性免疫治疗效果中的应用
EP4540284A2 (en) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 13 and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512402A (ja) * 2006-12-11 2010-04-22 ワイス エルエルシー Ｉｌ−１３関連障害を治療するための方法および組成物ならびにその治療をモニター観察するための方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP1631680A2 (en) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
CA2558366A1 (en) * 2004-02-23 2005-09-01 Erasmus Universiteit Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
WO2008091814A2 (en) * 2007-01-22 2008-07-31 Wyeth Assessment of asthma and allergen-dependent gene expression
US20120005206A1 (en) * 2007-02-09 2012-01-05 Konstantinos Anagnostakis Apparatus and method for analysis of data traffic
CN102099485A (zh) * 2007-10-23 2011-06-15 临床基因组学有限公司 诊断新生物的方法-ⅱ
RU2607569C2 (ru) 2008-03-31 2017-01-10 Дженентек, Инк. Композиции и способы для лечения и диагностики астмы
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
JP2013544235A (ja) * 2010-10-15 2013-12-12 メドイミューン・リミテッド 肺機能を改善する治療法
KR101615474B1 (ko) 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
US8961965B2 (en) 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512402A (ja) * 2006-12-11 2010-04-22 ワイス エルエルシー Ｉｌ−１３関連障害を治療するための方法および組成物ならびにその治療をモニター観察するための方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CORREN J, ET AL.: "Lebrikizumab treatment in adults with asthma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, no. 12, JPN6018039207, 2011, pages 1088 - 1098, XP009164420, ISSN: 0004298158, DOI: 10.1056/NEJMoa1106469 *
KIM ST, ET AL.: "Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the", THE JOURNAL OF GENE MEDICINE, vol. 11, no. 1, JPN6018039209, 2009, pages 26 - 37, XP093176074, ISSN: 0004092222, DOI: 10.1002/jgm.1268 *
LUN SW, ET AL.: "Increased expression of plasma and CD4+ T lymphocyte costimulatory molecule CD26 in adult patients w", JOURNAL OF CLINICAL IMMUNOLOGY, vol. 27, no. 4, JPN6018039208, July 2007 (2007-07-01), pages 430 - 437, XP019504043, ISSN: 0004092221, DOI: 10.1007/s10875-007-9093-z *
PIPER E, ET AL.: "A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma", THE EUROPEAN RESPIRATORY JOURNAL, vol. 41, no. 2, JPN6018039206, 2013, pages 330 - 338, ISSN: 0004298157 *
TASIC T, ET AL.: "Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 41, no. 8, JPN6018039212, 2011, pages 1098 - 1107, XP071887063, ISSN: 0004298159, DOI: 10.1111/j.1365-2222.2011.03778.x *

Also Published As

Publication number Publication date
RU2016134838A (ru) 2018-03-07
CA2937387A1 (en) 2015-07-30
EP3685857A1 (en) 2020-07-29
EP3099323A4 (en) 2017-10-04
SG11201606102UA (en) 2016-08-30
EP3099323A1 (en) 2016-12-07
RU2016134838A3 (enExample) 2018-09-27
BR112016017192A2 (pt) 2017-10-10
CN105934254A (zh) 2016-09-07
MX2016009491A (es) 2017-01-13
AU2015209124A1 (en) 2016-08-18
WO2015112970A1 (en) 2015-07-30
US20160363591A1 (en) 2016-12-15
KR20160113700A (ko) 2016-09-30

Similar Documents

Publication Publication Date Title
JP2017509692A (ja) 喘息肺におけるｉｌ−１３活性化の末梢バイオマーカーとしてのジペプチジルペプチターゼ４（ｄｐｐ４／ｃｄ２６）
Berthold et al. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden
Carpagnano et al. Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
Seys et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T (h) 2-high asthma patients
Pavanello et al. Inflammatory long pentraxin 3 is associated with leukocyte telomere length in night-shift workers
Combe et al. Early lessons from the recent-onset rheumatoid arthritis cohort ESPOIR
Diesler et al. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies
Wosiski-Kuhn et al. Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients
Shrestha Palikhe et al. Th2 cell markers in peripheral blood increase during an acute asthma exacerbation
JP2018538249A (ja) 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
Hachim et al. Confounding patient factors affecting the proper interpretation of the periostin level as a biomarker in asthma development
Wijsman et al. Airway inflammation before and after bronchial thermoplasty in severe asthma
Craig et al. Improving detection of alpha-1 antitrypsin deficiency: role of the allergist
JP2019523759A (ja) 関節リウマチの治療のための臨床応答バイオマーカーとしての抗ｐａｄ４自己抗体
Reihman et al. Management of severe asthma beyond the guidelines
RU2383019C1 (ru) Способ прогнозирования риска развития бронхиальной астмы
JP5399219B2 (ja) 関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
Shi et al. LncRNA HOTTIP as a diagnostic biomarker for acute respiratory distress syndrome in patients with sepsis and to predict the short-term clinical outcome: a case-control study
JPWO2010038840A1 (ja) 関節リウマチに対する抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
Alexeeva et al. Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method
Küster et al. Effects of systemic immunosuppressive therapies for moderate‐to‐severe eczema in children and adults
Mohammed et al. Interplay of clinical biomarkers in allergic asthma diagnosis and severity: A case-control study
Dahmani et al. The C-589T IL-4 single nucleotide polymorphism as a genetic factor for atopic asthma, eczema and allergic rhinitis in an eastern Algerian population
Suzukawa et al. High Serum TSLP Is Characteristic of Late‐Onset, Long‐Duration, Eosinophilic Asthma
Zhou et al. Soluble TAM receptor tyrosine kinases correlate with disease severity and predict the early responsiveness of sublingual immunotherapy in allergic rhinitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200707